Qx Therapeutics reports that the FDA has cleared the company’s initial Investigational New Drug application (IND) for investigating its lead investigational drug product, QXT-101.
The trial protocol is entitled “A Phase 2, randomized, double-blind, multicenter, placebo-controlled, dose-escalation study to evaluate the safety and efficacy of QXT-101 for the prevention and treatment of primary graft dysfunction in lung transplant recipients.”